Medical College of Wisconsin
Welcome,         Profile    Billing    Logout  
 2199 Trials 
5266 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Margolis, David J
NCT04582383: Comparative Effectiveness Study of Spironolactone Versus Doxycycline for Acne

Recruiting
4
400
US
Spironolactone, Doxycycline Hyclate
University of Pennsylvania
Acne
07/25
07/26
NCT01656603: Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation

Recruiting
2
9999
US
unlicensed CBU
New York Blood Center
Infusion Reactions
12/25
12/25
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Schneider, Robert
NCT05743023: Consciousness-based Ayurveda Lifestyle Program for Improving Quality of Life in Survivors of Breast Cancer

Active, not recruiting
N/A
15
US
Ayurvedic lifestyle protocol, personalized diet and daily routine protocol
Robert Schneider, MD
Breast Cancer Survivors
04/23
06/23
Collins, Michael T
NCT06474273: TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients

Not yet recruiting
4
540
Canada, RoW
Methylprednisolone, IV MP, Prednisone
University of Sydney, University of Manitoba
Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
12/29
12/29
ACHIEVE, NCT03020303 / 2020-001882-36: Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease

Recruiting
3
2750
Europe, Canada, RoW
Spironolactone 25Mg Tablet, Placebo Oral Tablet
Population Health Research Institute, Canadian Institutes of Health Research (CIHR)
Endstage Renal Disease
12/24
01/25
BEAT-Calci, NCT05018221: Better Evidence and Translation for Calciphylaxis

Recruiting
3
350
RoW
Vitamin K1, Phytonadione, Magnesium citrate, Sodium Thiosulfate, Intravenous Sodium Thiosulfate Injection, High Flux Dialyser, High Flux Hemodialysis, Medium Cut-off Dialyser, Medium Cut-off Hemodialysis, Placebo injection (normal saline), 0.9% sodium chloride solution, Placebo capsule (Vitamin K1), Matching placebo capsule, Placebo tablet (Magnesium citrate), Matching placebo tablet
University of Sydney, Australasian Kidney Trials Network, Northern Care Alliance NHS Foundation Trust, Waitemata District Health Board
Calciphylaxis
12/29
12/29
NCT05721573: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Active, not recruiting
2/3
231
Europe, Canada, US, RoW
ABC008
Abcuro, Inc., Syneos Health
Inclusion Body Myositis
11/25
12/25
NCT05735015: Study of the PTH-independent Effects of Encaleret on Mineral Homeostasis in Subjects With Postsurgical Hypoparathyroidism (PSH)

Recruiting
2
30
US
encaleret
National Institute of Dental and Craniofacial Research (NIDCR)
Post-Surgical Hypoparathyroidism
12/25
12/25
VARVARA, NCT05907096: ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function

Recruiting
2
102
Europe, Canada, RoW
ARGX-117, Placebo
argenx
Delayed Graft Function
04/26
12/26
FUSE-UK, NCT05708963: The U.K. Embryologist Fatigue Study

Completed
N/A
123
US
TMRW Life Sciences, Dudley Associates Healthcare Marketing & Communications
Fatigue, Stress, Burnout, Professional, Musculoskeletal Pain, Back Pain, Neck Pain, Headache, Dizziness, Sleep Disturbance, Chest Pain, Syncope, Cardiovascular Diseases, Shortness of Breath, Gastrointestinal Diseases
01/23
02/23
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial

Active, not recruiting
N/A
2005
US
Orbital Atherectomy, Balloon
Abbott Medical Devices, Cardiovascular Research Foundation, New York
Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction
06/24
06/25
TARGET-IV_NA, NCT04562532: Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

Active, not recruiting
N/A
1720
Europe, Canada, US
Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Shanghai MicroPort Medical (Group) Co., Ltd.
Coronary Artery Disease
06/24
06/27
T-MD, NCT04549532: Targeted Multidomain () Interventions for Complex Mild Traumatic Brain Injury (mTBI)

Active, not recruiting
N/A
169
US
Targeted Multidomain, Behavioral Management
University of Pittsburgh, Inova Health Care Services, United States Department of Defense
Concussion, Mild
10/24
10/25
BHI, NCT04708613: University of Pittsburgh Brain Health Initiative

Recruiting
N/A
300
US
Cognitive/Neuropsychological Testing, Vestibular/Ocular-Motor Testing, Sleep Evaluation, MRI, High-Resolution, Health & Physical Exam, Physical Function, Blood Testing and Biomarker Analysis, Applanation Tonometry, Continuous arterial pressure, PET brain imaging, [C-11]6-OH-BTA-1, Pittsburgh Compound B, [F-18]AV-1451, [F-18]T807, LY3191748
David Okonkwo, MD, PhD, National Football League Scientific Advisory Board, Avid Radiopharmaceuticals, Inc., Harvard University
Traumatic Brain Injury
12/24
12/24
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Fowler, Daniel H
NCT04220190: RAPA-501 Therapy for ALS

Not yet recruiting
2/3
41
US
RAPA-501 Autologous T cells, RAPA-501 cells
Rapa Therapeutics LLC, Massachusetts General Hospital, Hackensack Meridian Health
Amyotrophic Lateral Sclerosis
07/25
07/25
NCT04176380: RAPA-201 T Cell Therapy for Relapsed, Refractory Multiple Myeloma

Recruiting
2
27
US
RAPA-201 Autologous T cells, RAPA-201 cells
Rapa Therapeutics LLC, Medical College of Wisconsin
Relapsed, Refractory Multiple Myeloma
10/23
10/23
NCT05144698: RAPA-201 Therapy of Solid Tumors

Recruiting
1/2
22
US
RAPA-201 Rapamycin Resistant T Cells, RAPA-201 cells, Chemotherapy Prior to RAPA-201 Therapy
Rapa Therapeutics LLC
Solid Tumor, Breast Cancer, Small Cell and Non-small Cell Lung Cancer, Triple Negative Breast Cancer, Gastric Cancer, Esophageal Adenocarcinoma, Gastric Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of Larynx, Squamous Cell Carcinoma of Nasopharynx, Squamous Cell Carcinoma of Other Specified Sites of Skin, Carcinoma of Unknown Primary, Bladder Cancer, Malignant Melanoma
01/24
12/24
NCT06169176: RAPA-501 Therapy for ALS EAP

Available
N/A
US
RAPA-501 Autologous T cells
Rapa Therapeutics LLC, Massachusetts General Hospital, Hackensack Meridian Health
Amyotrophic Lateral Sclerosis
 
 
Graham, Mary V
NCT03462459: Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection

Completed
2
54
US
Vancomycin, Vancomycin Hydrochloride, Vancocin, Placebo
University of Wisconsin, Madison, Medical College of Wisconsin, Agency for Healthcare Research and Quality (AHRQ), Henry Ford Hospital, Mayo Clinic
Recurrent Clostridium Difficile Infection, Clostridium Difficile Infection, CDI, C.Difficile Diarrhea, C. Diff Colitis, C.Difficile Colitis
07/23
07/23
Cairo, Mitchell S
NCT03805581: Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Completed
2
20
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University
Sickle Cell Disease, Acute Chest Syndrome
07/22
11/23
NCT02117297: SCT Plus Immune Therapy in Average Risk AML/MDS

Completed
2
26
US
Gemtuzumab Ozogamicin, Mylotarg
New York Medical College
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
03/23
03/23
NCT02221310: Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Completed
2
25
US
Gemtuzumab Ozogamicin, Mylotarg
New York Medical College
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
04/23
04/23
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
HaploSCD, NCT01461837: Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

Active, not recruiting
2
21
US
CD34 selected T-cell depleted allogeneic SCT, Familial haploidentical, T-cell depleted, allogeneic stem cell transplantation, high risk Sickle Cell Disease
New York Medical College, UCSF Benioff Children's Hospital Oakland, Medical College of Wisconsin, Washington University School of Medicine, Tufts Medical Center, University of California, San Francisco, University of California, Los Angeles, Miltenyi Biomedicine GmbH, Ann & Robert H Lurie Children's Hospital of Chicago
Sickle Cell Disease
12/24
12/25
NCT03266640: Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)

Recruiting
2
20
US
viral specific cytotoxic t-lymphocytes, CMV CTLs
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco, Washington University School of Medicine, Indiana University, Children's Hospital Los Angeles
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
08/24
12/24
NCT03266627: Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection

Recruiting
2
20
US
cytotoxic t-lymphocytes, viral specific CTLs
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco, University of Colorado, Denver, Indiana University, Washington University School of Medicine, University of California, Los Angeles
Adenovirus, Primary Immune Deficiency Disorder
08/24
12/24
NCT03266653: EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Recruiting
2
20
US
cytotoxic t-lymphocytes, CTLs
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Indiana University, Washington University School of Medicine, University of California, Los Angeles, University of California, San Francisco
Epstein-Barr Virus Infections, Primary Immune Deficiency Disorder
08/24
12/25
O-ICE, NCT02393157: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting
2
25
US
Obinutuzumab, Gazyva, Liposomal ARA-C, Depocyte, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16
New York Medical College, Roswell Park Cancer Institute
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
12/24
12/24
NYMC-571, NCT02675959: Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Recruiting
2
40
US
Defibrotide
New York Medical College, University of California, Los Angeles, Medical College of Wisconsin, Tufts Medical Center, Baylor College of Medicine, Johns Hopkins University, Dana-Farber Cancer Institute, Children's Hospital Los Angeles
Sickle Cell Disease
12/24
12/25
NCT04099966: AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Recruiting
2
20
US
alpha beta depletion, α/β CD3+/CD19+ cell depletion
Mitchell Cairo
Acute Leukemia, Severe Aplastic Anemia, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Kostmann, Diamond Blackfan Anemia, Amegakaryocytic Thrombocytopenia, Sickle Cell Disease, Beta-Thalassemia
12/25
12/26
NCT05987124: Defibrotide Dose-escalation for SOS Post-HSCT

Recruiting
2
20
US
Defibrotide, Defitelio
New York Medical College
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
08/26
08/27
NCT05564598: CMV CTLs in Neonates With CMV Infection

Recruiting
2
23
US
CMV Cytotoxic T-Lymphocytes, CTLs, Anti-viral Therapy, valganciclovir, ganciclovir
New York Medical College
Congenital Cytomegaloviral (CMV) Disease
10/27
10/28
RADICAL, NCT05253495: Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Recruiting
2
80
US
DOC Group B, Reduction Phase, Pv-COMRAD 1 and 2 Group B, Induction 1 and 2, Pv-R-CYM 1 and 2 Group B, Consolidation 1 and 2, DOC Group C, Reduction with IT, MAD CPR 1 and 2, Induction 1 and 2 Group C, Pv-R CYVE 1 and 2, Consolidation 1 and 2 Group C CNS Negative, Pv-R CYVE-MTX 1 and 2, Consolidation 1 and 2 Group C CNS Positive, MAD CP, Maintenance 1 Group C, Pv-Cytarabine/etoposide, Maintenance 2, 4 Group C, AD CP, Maintenance 3 Group C, Bv-AVD-R 1 and 2: COHORT IIa, Intermediate Risk cohort IIa, Bv-NVD-R, Cycle 1-2, Cohort IIa Rapid Early Responders, Bv-NVD-R, Cycle 1-4 SER, Cohort IIa Slow Early Responders, Bv-AVD-R, High-Risk cohort IIb, Bv-NVD-R, Cycle 1-4 RER, cohort IIb Rapid Early Responders, Bv-NAVD-R, Cycle 1-2, cohort IIb Slow Early Responders, Involved Site Radiation Therapy, Cohort II ONLY
New York Medical College
Non-hodgkin Lymphoma, Hodgkin Lymphoma
12/27
06/28
NCT02098512: Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Active, not recruiting
1/2
20
US
Brentuximab Vedotin, Adcetris, Allogeneic Stem Cell Transplantation, Reduced Intensity Conditioning
New York Medical College, St. Baldrick's Foundation
Hodgkin Lymphoma
12/21
12/22
NCT04197596: Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Recruiting
1/2
40
US
BK CTL
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital, Johns Hopkins University, University of California, San Francisco
Viral Infection, Primary Immune Deficiency Disorder
12/24
06/25
NCT04896606: SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

Recruiting
1/2
50
US
Standard of Care, SARS-CoV2-CTLS
New York Medical College, Children's Hospital of Philadelphia, Medical College of Wisconsin, Nationwide Children's Hospital
Covid19
12/24
12/25
NCT05286801: Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Recruiting
1/2
86
Canada, US, RoW
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tiragolumab, MTIG7192A, RG6058, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
National Cancer Institute (NCI)
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm, Poorly Differentiated Chordoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Recurrent Epithelioid Sarcoma, Recurrent Kidney Medullary Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Rhabdoid Tumor, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Kidney Medullary Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Rhabdoid Tumor, Rhabdoid Tumor
09/25
09/25
NCT04870944: CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recruiting
1/2
95
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspirate, BONE MARROW, LIQUID, Human Bone Marrow Aspirate, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, FACT Complex-targeting Curaxin CBL0137, CBL0137
Children's Oncology Group, Incuron LLC, National Cancer Institute (NCI)
Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Malignant Neoplasm in the Central Nervous System, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Recurrent Primary Malignant Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma, Refractory Primary Malignant Central Nervous System Neoplasm
12/26
12/26
CYNK001AML01, NCT04310592: Natural Killer Cell (CYNK-001) Infusions in Adults With AML

Recruiting
1
94
US
CYNK-001
Celularity Incorporated
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Neoplasms by Histologic Type, Neoplasms, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Alkylating Agents, Antimetabolites, Antineoplastic, Antiviral Agents, Analgesics, Non-narcotic, Anti-infective Agents, Analgesics, Peripheral Nervous System Agents, Hematologic Diseases, Hematologic Neoplasms, Leukemia in Remission, Relapsed Adult AML, Refractory AML
06/24
12/24
NCT03719105: Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Recruiting
1
40
US
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
New York Medical College, University of Alabama at Birmingham
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
12/25
12/26
ALLO-T-DART, NCT04972942: Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma

Recruiting
1
30
US
Daratumumab, Darzalex®
New York Medical College
T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
09/27
09/28
NCI-2022-03576, NCT05359237: Vincristine Pharmacokinetics in Infants

Recruiting
N/A
74
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Vincristine, LCR, Leurocristine, VCR, Vincrystine
Children's Oncology Group, National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
07/24
07/24
NCT01351545: A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Recruiting
N/A
99999
US
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
10/41
10/41
Vesole, David H
NCT04700176: A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Terminated
2
1
US
Daratumumab, Darzalex, Pomalidomide, Pomalyst, All-trans retinoic acid, ATRA, Dexamethasone, Decadron
Hackensack Meridian Health, Janssen, LP
Multiple Myeloma
11/23
11/23
Dara-MGUS, NCT06046287: Daratumumab for Polyneuropathy Associated With MGUS

Recruiting
2
20
US
Daratumumab and hyaluronidase-fihj, Darzalex Faspro
Georgetown University, Janssen, LP
Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance
12/26
12/26
CarMob, NCT03909412: Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

Suspended
1
18
US
Carfilzomib, Kyprolis, Cyclophosphamide, Cytoxan, Dexamethasone, Decadron, Granulocyte Colony-Stimulating Factor, G-CSF, Filgrastim, Neupogen
Hackensack Meridian Health, Amgen
Multiple Myeloma
12/24
12/24
NCT02332850: Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
83
Canada, US
Isatuximab, SAR 650984, Carfilzomib, Kyprolis, PR-171, Dexamethasone, Orgadrone, Spersadex, Visumetazone
Thomas Martin, MD, Amgen, Sanofi
Multiple Myeloma
12/24
12/24
DREAMM 12, NCT04398745: A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Recruiting
1
36
Europe, US, RoW
Belantamab mafodotin, GSK2857916
GlaxoSmithKline
Multiple Myeloma
02/25
02/25
DREAMM 13, NCT04398680: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function

Recruiting
1
28
Europe, US, RoW
Belantamab mafodotin
GlaxoSmithKline
Multiple Myeloma
11/25
11/25
Lawton, Colleen A
INNOVATE, NCT04134260: Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer

Recruiting
3
586
US
Apalutamide, ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927, Hormone Therapy, Chemotherapy-Hormones/Steroids, Endocrine Therapy, Hormonal Therapy, hormone treatment, Hormones, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
11/26
11/26
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Active, not recruiting
2
188
Canada, US
Radiation Therapy, RT, Three-Dimensional Conformal Radiation Therapy (3D-CRT), Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoldaex®, Trelstar®
RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc
Prostate Cancer
04/23
09/29
NADIR, NCT04037254: Niraparib With Standard Combination Radiation Therapy and Androgen Deprivation Therapy in Treating Patients With High Risk Prostate Cancer

Suspended
2
180
Canada, US
Gonadotrophin Releasing Hormone, AY-24031, D-His-6-Pro-8-NEt-LHRH, Follicle Stimulating Hormone-Releasing Factor, GN-RH, GnRH, Gonadoliberin, Gonadorelin, Gonadorelinum, gonadotropin-releasing hormone, Hoe- 471, LH-RF, LH-RH, LH/FSH-RF, LH/FSH-RH, LHRH, Luliberin, Luteinising Hormone-Releasing Factor, Luteinizing Hormone-Releasing Factor, luteinizing hormone-releasing hormone, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Niraparib, MK-4827, MK4827
NRG Oncology, National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
01/28
12/28
NCT02177292: High-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB)

Active, not recruiting
N/A
80
US
Radiation Therapy, Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).
Medical College of Wisconsin
Prostate Cancer
06/26
06/30
Trachtman, Howard
DUET, NCT01613118 / 2014-002358-38: Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Checkmark Data from DUET trial for focal segmental glomerulosis at ASN Kidney Week 2020
Oct 2020 - Oct 2020: Data from DUET trial for focal segmental glomerulosis at ASN Kidney Week 2020
Checkmark DUET study in focal segmental glomerulosclerosis
Feb 2020 - Feb 2020: DUET study in focal segmental glomerulosclerosis
Completed
2
109
Europe, US, RoW
RE-021 (Sparsentan), Sparsentan, Irbesartan, Avapro
Travere Therapeutics, Inc.
Focal Segmental Glomerulosclerosis
06/16
03/24
NEPTUNE, NCT01209000: Nephrotic Syndrome Study Network

Recruiting
N/A
1200
Canada, US
Kidney Biopsy
University of Michigan, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The NephCure Foundation
Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
06/26
06/26
Weinberg, David V
NCT04173169: Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis

Active, not recruiting
3
112
US
Elagolix 200 MG, Orlissa, Placebo or SOC IVF
Yale University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Colorado, Denver, Northwestern University, University of North Carolina
Infertility, Endometriosis
05/25
05/25
FRIEND, NCT05364008: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea

Recruiting
3
50
US
Green Tea Extract, EGCG (epigallocatechin gallate), Placebo
Yale University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Chicago, University of Illinois at Chicago, Johns Hopkins University
Leiomyoma, Uterine
12/25
12/25
NCT02886000: Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

Recruiting
2
120
US
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Quality of Life Assessment, Saline, Sodium Chloride 0.9%
Mayo Clinic, National Cancer Institute (NCI)
Colorectal Adenoma, Colorectal Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
02/17
 
SAFE Study, NCT04907084: Serine and Fenofibrate Study in Patients With MacTel Type 2

Active, not recruiting
2
60
Europe, US
Serine, Fenofibrate
The Lowy Medical Research Institute Limited
Macular Telangiectasia Type 2
03/24
03/24
NCT03796884: Linaclotide in Treating Patients With Stages 0-3 Colorectal Cancer

Active, not recruiting
2
230
US
Linaclotide, 851199-59-2, Linzess, [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide, L-Tyrosine, L-cysteinyl-L-cysteinyl-L-alpha-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L- asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteiny, cyclic (1->6), (2->10), (5->13)-tris(disulfide), MD-1100, Placebo
Sidney Kimmel Cancer Center at Thomas Jefferson University, United States Department of Defense
Colorectal Adenoma, Stage 0 Colorectal Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
06/25
06/25
NCT05107219: GCC Agonist Signal in the Small Intestine

Recruiting
1
43
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Esophagogastroduodenoscopy, EGD, Linaclotide, [9-L-tyrosine]heat-stable enterotoxin (Escherichia coli)-(6-19)-peptide, Linzess, MD-1100, Plecanatide, Trulance
National Cancer Institute (NCI)
Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
02/25
02/25
PRECEDE, NCT04970056: Pancreatic Cancer Early Detection Consortium

Recruiting
N/A
8000
Europe, Canada, US, RoW
Arbor Research Collaborative for Health
Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
12/30
12/30
EA2185, NCT04239573: Comparing Two Methods to Follow Patients With Pancreatic Cysts

Recruiting
N/A
4606
Canada, US, RoW
Computed Tomography, CAT, CAT scan, Computerized Axial Tomography, computerized tomography, CT, CT scan, tomography, Endoscopic Ultrasound, endosonography, EUS, Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Pancreatic Carcinoma
07/33
07/33
Thomas, James P
Lung-MAP Non-Match Sub-Study, NCT05096663: Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Checkmark Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Apr 2022 - Apr 2022: Initiation of Lung-MAP trial in combination with Keytruda for 2L NSCLC
Active, not recruiting
2/3
82
US
Cobalamin, B12 Vitamin, Cobalamin (1+), VIT B12, Vitamin B-12, Vitamin B12, Vitamin-B12, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Docetaxel, Docecad, RP56976, Taxotere, Taxotere Injection Concentrate, Folic Acid, 2-[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]aminopentanedioic acid, FA, Folacin, Pteroylmonoglutamic Acid, Vitamin B9, Vitamin Bc, Gemcitabine, dFdC, dFdCyd, Difluorodeoxycytidine, Nogapendekin Alfa, ALT 803, ALT-803, ALT803, Fusion Protein Consisting of IL-15N72D and IL-15RaSu/FC, IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, N 803, N-803, N803, Superagonist Interleukin-15:Interleukin-15 Receptor AlphaSu/Fc Fusion Complex Alt-803, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Ramucirumab, Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B, Cyramza, IMC-1121B, LY3009806, Monoclonal Antibody HGS-ETR2
SWOG Cancer Research Network, National Cancer Institute (NCI)
Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
02/27
12/27
STARS, NCT05363397: Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

Recruiting
2
80
RoW
TBO-309
The George Institute, Heart Research Institute
Acute Ischemic Stroke
02/25
05/25
IMPACT, NCT05989711: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH) ( Trial)

Recruiting
2
190
US, RoW
Pemvidutide, Placebo
Altimmune, Inc.
Non-Alcoholic Steatohepatitis (NASH)
02/25
09/25
VIGOR, NCT03463824: The Study - Virtual Immersive Gaming to Optimize Recovery in Low Back Pain

Completed
N/A
159
US
Experimental Group 1, Experimental Group 2
Virginia Commonwealth University, Ohio University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Chronic Low Back Pain, Fear of Pain, Fear of Injury
10/23
10/23
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
NCT04092803: Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu

Recruiting
N/A
20
US
Virtual Reality
University of Colorado, Denver, National Cancer Institute (NCI)
Leukemia
06/24
06/25
Burroughs, Lauri
NCT01659606: Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

Active, not recruiting
2
40
Europe, US
alemtuzumab, Campath-1H, Fludarabine, Fludara, Cyclosporins, cyclosporine A, Neoral, Sandimmune, Mycophenolate mofetil, Cellcept, Tacrolimus, FK506, Prograf
Boston Children's Hospital, Dana-Farber Cancer Institute, Children's Hospital Medical Center, Cincinnati, Children's Hospital Los Angeles, Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Baylor College of Medicine, Children's Hospital of Philadelphia, University of Wisconsin, Madison, Karolinska University Hospital, Hackensack Meridian Health, Duke University, Oslo University Hospital, Children's Mercy Hospital Kansas City, Mayo Clinic, University of Chicago, Massachusetts General Hospital
Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
04/24
12/34
NCT04965597: Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

Recruiting
2
40
US
Treosulfan, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon, Trecondi, Fludarabine Phosphate, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, 9H-purin-6-amine, 2-fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl), Beneflur, Fludara, Fludarabine-5'-Monophosphate, SH T 586, Tacrolimus, FK 506, Fujimycin, Hecoria, Prograf, Protopic, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, Emthexat, Emtexate, Farmitrexat, Methotrexate LPF, Methylaminopterin, Methotrexatum, Metotrexato, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Lapine T-Lymphocyte Immune Globulin, Anti-Thymocyte Globulin Rabbit, Grafalon, Rabbit Anti-Human Thymocyte Globulin (RATG), Rabbit Anti-Thymocyte Globulin, Rabbit Antithymocyte Globulin, Rabbit ATG, rATG, Thymoglobulin, Antithymocyte globulin rabbit ATG, Imtix, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, peripheral stem cell support, Peripheral Stem Cell Transplant, peripheral stem cell transplantation, Allogeneic Bone Marrow Transplantation, Allo BMT, Allogeneic Blood and Marrow Transplantation, Allogeneic BMT, Quality-of-Life Assessment, Quality of Life Assessment, Echocardiography, EC, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, Multi-Gated Acquisition Scan, MUGA Scan, Radionuclide Ventriculogram Scan, Radionuclide ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection, Biological Sample Collection, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Computed Tomography, Computed Axial Tomography, CAT Scan, CT Scan
Fred Hutchinson Cancer Center, Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, National Heart, Lung, and Blood Institute (NHLBI)
Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
12/25
12/26
CSIDE, NCT03619551: Conditioning SCID Infants Diagnosed Early

Recruiting
2
64
Canada, US
Busulfan, Cell processing for TCRαβ+/CD19+ depletion, CliniMACS
Michael Pulsipher, MD
SCID
08/26
08/26
NCT03980769: Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders

Recruiting
2
40
US
Thiotepa, 1,1',1"-phosphinothioylidynetrisaziridine, N,N', N''-Triethylenethiophosphoramid, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Triethylene thiophosphoramide, Triethylenethiophosphoramide, TSPA, Treosulfan, (S-(R*,R*))-1,2,3,4-butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-, 299-75-2, 39069, Dihydroxybusulfan, Ovastat, Treosulphan, Tresulfon, Fludarabine Phosphate, 2-F-ara-AMP, 312887, 328002, 75607-67-9, 9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-, Beneflur, Fludara, Fludarabine-5'-Monophosphate, Rabbit Anti-Thymocyte Globulin, Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Cell Transplantation, Allogeneic Stem Cell Transplantation, HSC, HSCT
Fred Hutchinson Cancer Center
Non-Neoplastic Hematologic and Lymphocytic Disorder
07/27
07/27
DiPersio, John F
GENESIS, NCT03246529 / 2018-001715-79: A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous TransplantatIon in Subjects With MM

Active, not recruiting
3
180
Europe, US
BL-8040 1.25 mg/kg + G-CSF, Placebo +G-CSF
BioLineRx, Ltd.
Multiple Myeloma
12/20
09/29
NCT02782546: Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation

Recruiting
2
60
US
Graft cell infusion, HCT, Tacrolimus, Prograf, Mycophenolate mofetil, CellCept, Myfortic, G-CSF, Granulocyte-colony stimulating factor, CIML NK cell infusion, ALT-803, Leukapheresis
Washington University School of Medicine, National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI), ImmunityBio, Inc.
Acute Myeloid Leukemia
01/26
01/26
NCT04582864: Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

Recruiting
2
25
US
Flotetuzumab, MGD006, Donor lymphocyte infusion, DLI
Washington University School of Medicine, MacroGenics, National Cancer Institute (NCI)
Relapsed Acute Myeloid Leukemia
07/28
06/29
NCT04354025: Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Withdrawn
2
48
NA
Cytokine induced memory-like NK cells, CIML NK cells, Fludarabine, Ara-C, Cytarabine, G-CSF, Filgrastim, Interleukin-2, IL-2, Leukapheresis
Washington University School of Medicine
Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia
09/26
07/28
NCT05820763: Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Recruiting
2
35
US
Selinexor, EXPOVIO, KPT-330, Lenalidomide, Revlimid, Dexamethasone, Decadron
Washington University School of Medicine, Karyopharm Therapeutics Inc
Multiple Myeloma, Myeloma-Associated Amyloidosis
01/27
01/27
NCT04331119: Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas

Recruiting
2
36
US
Duvelisib, Copiktra, Peripheral blood draw
Washington University School of Medicine, SecuraBio
T-Cell Lymphoma
07/27
07/27
NCT02756962: Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Active, not recruiting
2
107
US
Cytarabine, Ara-C, Cytosar-U, Tarabine-PFS, AraC, Allogeneic stem cell transplant, AlloSCT, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Washington University School of Medicine, The Leukemia and Lymphoma Society, American Society of Hematology
Acute Myeloid Leukemia
07/33
07/33
VBP101, NCT04849910: Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Recruiting
1/2
24
Canada, US
VOR33, Mylotarg, gemtuzumab ozogamicin
Vor Biopharma
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
02/25
01/27
VBP301, NCT05984199: Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant

Recruiting
1/2
24
US
VCAR33
Vor Biopharma
Leukemia, Myeloid, Acute
12/24
11/26
NCT05886491: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
1/2
53
US
GDX012, Chemotherapy Agents
Takeda
Leukemia
04/26
06/27
NCT03687957: rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide

Recruiting
1/2
70
US
rhIL-7-hyFc, Placebo, Temozolomide, TMZ, Radiation therapy, RT, Blood sample
Washington University School of Medicine, NeoImmuneTech, The Foundation for Barnes-Jewish Hospital
Glioma
01/32
01/32
NCT04912427: Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

Terminated
1
1
US
Isatuximab, Sarclisa, Bortezomib, Velcade, Dexamethasone
Washington University School of Medicine, Sanofi
Multiple Myeloma
12/22
01/24
NCT04006652: ApoGraft for the Prevention of Acute Graft Versus Host Disease in Haploidentical Hematopoietic Cell Transplant Recipients

Terminated
1
4
US
ApoGraft
Washington University School of Medicine, Cellect Biotechnology
Acute Graft Versus Host Disease, Haploidentical Hematopoietic Stem Cell Transplant
12/22
12/22
NCT04083898: Isatuximab, Bendamustine, and Prednisone in Refractory Multiple Myeloma

Hourglass Apr 2020 - Jun 2020 : From trial in combination with bendamustine for penta-refractory multiple myeloma
Terminated
1
15
US
Isatuximab, Bendamustine, Bendeka, Treanda, Prednisone, Deltasone, Rayos, Prednisone Intensol
Washington University School of Medicine, Sanofi
Multiple Myeloma
03/23
03/24
NCT05618301: Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Recruiting
1
10
US
Motixafortide, BL-8040, Natalizumab, Tysabri, Leukapheresis
Washington University School of Medicine, BioLineRx, Ltd., Biogen
Sickle Cell Disease
12/25
12/25
haplo-HCT, NCT03755414: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Active, not recruiting
1
55
US
Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), Human Activity Profile
Washington University School of Medicine, Incyte Corporation, American Society of Hematology, National Cancer Institute (NCI)
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Disease
06/24
09/24
NCT06185751: Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma

Not yet recruiting
1
25
US
WS-CART-CS1, Lymphodepleting chemotherapy
Washington University School of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research
Multiple Myeloma
06/29
06/40
NCT05787496: A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Recruiting
1
63
US
NC525
NextCure, Inc.
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
05/25
05/25
NCT05044039: Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy

Recruiting
1
43
US
Duvelisib
Washington University School of Medicine, SecuraBio, The Foundation for Barnes-Jewish Hospital, National Cancer Institute (NCI)
Non-hodgkin Lymphoma, Acute Lymphocytic Leukemia
12/25
05/30
NCT05412290: Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

Recruiting
1
15
US
Mosunetuzumab, RO7030816, BTCT4465A
Washington University School of Medicine, Genentech, Inc.
B Cell Lymphoma, Aggressive Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma, Follicular Lymphoma Grade 3
07/27
06/29
NCT06008808: Ruxolitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Recruiting
1
49
US
Ruxolitinib, Jakafi
Washington University School of Medicine, Incyte Corporation
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
09/26
12/26
NCT05377827: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies

Recruiting
1
54
US
WU-CART-007
Washington University School of Medicine, Wugen, Inc.
T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma, Adult T Cell Leukemia, Adult T Cell Lymphoma, T Cell Prolymphocytic Leukemia, Extranodal NK/T-cell Lymphoma, Transformed Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma
04/26
04/26
NCT05918913: Expanded Access Program for Revumenib

Available
N/A
US
Revumenib, SNDX-5613
Syndax Pharmaceuticals
Relapsed/Refractory Acute Leukemia
 
 
NCT04614987: Serum Neurofilament Light (NfL) as a Marker for Brain Injury in Individuals Undergoing Chimeric Antigen Receptor-modified T Therapy

Terminated
N/A
17
US
Washington University School of Medicine, McDonnell Center, Paula and Roger Riney Blood Cancer Research
Neurotoxicity
09/23
09/23
NCT02611180: Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease

Recruiting
N/A
50
US
Skin punch biopsy, Peripheral blood draw
Washington University School of Medicine
Acute Graft-versus-host Disease, Acute GVHD, Chronic Graft-versus-host Disease, Chronic GVHD
04/25
04/25
 

Download Options